Figure 8. Concurrent miR-30c^lo Serpine1^hi expression cumulatively predicts decreased patient survival in a large cohort of breast cancer patients.

(A) METABRIC data were downloaded from the Sage BioNetworks Synapse database (https://www.synapse.org/#!Synapse:syn1688369/wiki/27311). mRNA and miRNA expression data and clinical overall survival data from approximately 1285 patients were examined. SERPINE1 expression in a large cohort of breast cancer patients from a METRABRIC data set is shown. SERPINE1^hi is defined as patients with SERPINE1 expression higher than the median SERPINE1 expression level. SERPINE1^lo is defined as patients with SERPINE1 expression levels lower than or equal to the median SERPINE1 expression level. (B) miR-30c expression in breast cancer patients from the METABRIC data set. Definitions similar to those described above for SERPINE1 were used for patients’ miR-30c^hi and miR-30c^lo expression levels. (C) Concurrent expression of miR-30c and SERPINE1 in patients with breast cancer from the METRABIC data set. SERPINE1^lo miR-30c^hi is defined as patients with SERPINE1 expression lower than the median SERPINE1 expression level and miR-30c expression higher than the median miR-30c expression level. SERPINE1^hi miR-30c^lo is defined as patients with SERPINE1 expression higher than the median SERPINE1 expression level and miR-30c expression lower than the median miR-30c expression level. The remaining patients were defined as “others.” (D) SERPINE1 expression across breast cancer subtypes in The Cancer Genome Atlas Breast-Invasive Carcinoma (TCGA-BRCA) data set. TCGA breast cancer data were downloaded from the FireBrowse database (http://firebrowse.org/). mRNA and miRNA expression data and PAM50 subtypes were examined. (E) miR-30c expression across breast cancer subtypes in the TCGA-BRCA data set.